Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TELA Bio ( (TELA) ) has provided an update.
On March 24, 2026, TELA Bio reported that fourth-quarter 2025 revenue rose 18% year over year to a record $20.9 million and full-year 2025 revenue grew 16% to $80.3 million, driven by new customers, the U.S. launch of a larger OviTex PRS configuration and higher international sales, despite pricing pressure from a shift toward smaller hernia products. Gross margins improved for both the quarter and full year, operating expenses were essentially flat in 2025, operating losses narrowed slightly, and the company ended the year with $50.8 million in cash, buttressed by a new credit facility of up to $70 million, an expanded 88-representative sales force and a new chief medical officer as management seeks to advance toward profitability.
TELA Bio also provided 2026 guidance calling for at least 8% revenue growth over 2025 and projected first-quarter 2026 revenue of about $18.5 million, signaling a more moderate growth trajectory after a strong 2025. Management emphasized that the strengthened commercial infrastructure and added financing capacity are intended to support deeper penetration into key U.S. markets while reducing the need for additional capital raises, developments that may be closely watched by investors given the company’s continuing but narrowing operating losses.
The most recent analyst rating on (TELA) stock is a Hold with a $0.84 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
Spark’s Take on TELA Stock
According to Spark, TipRanks’ AI Analyst, TELA is a Neutral.
TELA Bio’s overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and ongoing losses. Technical analysis and valuation further weigh down the score due to bearish trends and a negative P/E ratio. Despite these challenges, the company is taking strategic steps to improve its financial position and operational efficiency, as highlighted in the earnings call and recent corporate events.
To see Spark’s full report on TELA stock, click here.
More about TELA Bio
TELA Bio, Inc. is a commercial-stage medical technology company specializing in advanced soft-tissue reconstruction solutions that prioritize preservation and restoration of the patient’s own anatomy. The company focuses on providing surgeons with clinically and economically effective alternatives to permanent synthetic materials, targeting soft-tissue repair markets in the U.S. and internationally.
Average Trading Volume: 163,580
Technical Sentiment Signal: Sell
Current Market Cap: $36.96M
Learn more about TELA stock on TipRanks’ Stock Analysis page.